Avastin (bevacizumab) - Angiogenesis Inhibitor and Cancer Therapy

Print-Icon
Print

Avastin has become the first angiogenesis inhibitor to market; it secured US FDA approval at the end of February 2004 for use as a first-line treatment for patients with metastatic colorectal cancer.
 
Next»




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development